XML 92 R69.htm IDEA: XBRL DOCUMENT v3.8.0.1
Joint Ventures and Other Equity Method Affiliates - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 1998
Dec. 31, 1993
Equity Income from Affiliates [Line Items]            
Equity income from affiliates   $ (42) $ (86) $ (205)    
Investments in affiliates accounted for using the equity method $ 715 767 715      
Contingent consideration $ 891 935 891 590    
Proceeds from sale of intangible assets   85 170      
Discount rate (as percent) 11.50%          
Other intangibles, net $ 17,305 14,183 17,305      
Gardasil/Gardasil 9            
Equity Income from Affiliates [Line Items]            
Other intangibles, net 468 468 468      
Step Acquisition and Termination of SPMSD            
Equity Income from Affiliates [Line Items]            
Investments in affiliates accounted for using the equity method $ 183   $ 183      
Equity interest acquired (as percent) 50.00%   50.00%      
Consideration transferred in business combination $ 657          
Royalty rate (as percent) 11.50%          
Contingent consideration $ 416   $ 416      
Proceeds from sale of intangible assets 596          
Fair value of future royalties $ 302   302      
Discount rate (as percent) 8.00%          
Transaction costs $ 24          
AstraZeneca LP            
Equity Income from Affiliates [Line Items]            
Ownership percentage (as percent)           50.00%
Limited partner interest in AZLP (as percent)         1.00%  
General partner interest in AZLP (as percent)         99.00%  
Other Noncash Income   232 98 182    
Other Receivables   $ 325        
Sanofi Pasteur MSD            
Equity Income from Affiliates [Line Items]            
Equity Method Investment, Summarized Financial Information, Revenue     $ 1,000 $ 923